图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫学评论综述™
影响因子: 1.352 5年影响因子: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 打印: 1040-8401
ISSN 在线: 2162-6472

免疫学评论综述™

DOI: 10.1615/CritRevImmunol.v18.i1-2.70
pages 55-63

Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity

Licia Rivoltini
Istituto Nazionale dei Tumori, Milano, Italy
Douglas J. Loftus
laboratory of Cell Biology ,National Cancer Institute, NIH, Bethesda MD, USA
Paola Squarcina
Istituto Nazionale dei Tumori, Milano, Italy
Chiara Castelli
Istituto Nazionale dei Tumori, Milano, Italy
Francesca Rini
Istituto Nazionale dei Tumori, Milano, Italy
Flavio Arienti
Istituto Nazionale dei Tumori, Milano, Italy
Filiberto Belli
Istituto Nazionale dei Tumori, Milano, Italy
Francesco M. Marincola
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
Carsten Geisler
Institute of Medical Microbiology and Immunology, University of Copenhagen, Denmark
Alessandro Borsatti
lstituto "M. Negri", Milano, Italy
Ettore Appella
laboratory of Cell Biology ,National Cancer Institute, NIH, Bethesda MD, USA
Giorgio Parmiani
Istituto Nazionale dei Tumori, Milano, Italy

ABSTRACT

Several T cell-recognized epitopes presented by melanoma cells have been identified recently. Despite the large array of epitopes potentially available for clinical use, it is still unclear which of these antigens could be effective in mediating anti-tumor responses when used as a vaccine. Preliminary studies showed that immunization of melanoma patients with epitopes derived from proteins of the MAGE family may result in significant clinical regressions. However, no sign of systemic immunization could be observed in peripheral blood of treated patients. Conversely, significant immunization (detected as increased antigen-specific CTL activity in peripheral blood) was obtained by vaccinating HLA-A2.1+ melanoma patients with the immunodominant epitope (residues 27-35) of the differentiation antigen MART-1, but this immunization was not accompanied by a significant clinical response. To implement immunotherapeuties capable of significantly impacting disease outcome, it is necessary to identify the potential mechanisms responsible for the failure of some antigens to mediate significant anti-tumor responses in vivo. In the case of the MART-127.35 epitope, we hypothesize that one of these mechanisms may be related to the existence of natural analogs of this peptide in other human normal proteins.


Articles with similar content:

Tumor-Specific Immune Response: Current In Vitro Analyses May Not Reflect the In Vivo Immune Status
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Philippe Kourilsky, Florence Faure, Jos Even
Autoimmune Pathogenesis of Multiple Sclerosis: Role of Autoreactive T Lymphocytes and New Immunotherapeutic Strategies
Critical Reviews™ in Immunology, Vol.17, 1997, issue 1
Piet Stinissen, Jef Raus, Jingwu Zhang
Dendritic Cells, Interleukin 12, and CD4+ Lymphocytes in the Initiation of Class l-restricted Reactivity to a Tumor/Self Peptide
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Emira Ayroldi, Maria Laura Belladonna, Maria Cristina Fioretti, Daniela Surace, Silvia Silla, Paolo Puccetti, Ursula Grohmann, Roberta Bianchi
T-Cell Receptor-Derived Peptides in Immunoregulation and Therapy of Retrovirally Induced Immunosuppression
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Ian F. Robey, Ronald R. Watson, R. Tomas Sepulveda, Allen B. Edmundson, John J. Marchalonis
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Brian J. Czerniecki, Jorgen Kjaergaard, Liaomin Peng, Peter A. Cohen, Gary K. Koski, James H. Finke, Suyu Shu, Gregory E. Plautz